SCHEMBL7256592

SCHEMBL7256592

O=[N+]([O-])c1cccc(-c2cocn2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.55
NPC1 O15118 5/20 0.55
IDO1 P14902 1/20 0.54
MAPT P10636 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ALDH1A1 P00352 3/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
KEAP1 Q14145 2/20 0.49
NFE2L2 Q16236 2/20 0.49
GRM5 P41594 1/20 0.48
PLK1 P53350 1/20 0.48
THRB P10828 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646144 0.83 ALDH1A1 (0.50) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL1647496 0.81 RAB9A (0.47) RAB9ANPC1MAPTALDH1A1LMNA
SCHEMBL30461136 0.80 RAB9A (0.69) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL30461135 0.80 RAB9A (0.69) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL6738366 0.76 TSHR (0.76) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL21952859 0.76 SCN9A (0.38) RAB9ANPC1IDO1MAPTALDH1A1
SCHEMBL9272513 0.76 MAPT (0.54) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL6231939 0.75 RAB9A (0.60) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL2643483 0.75 NPC1 (0.67) RAB9ANPC1IDO1MAPTSMN1; SMN2
SCHEMBL29496950 0.75 NPC1 (0.67) RAB9ANPC1IDO1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3852736-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Metacrine, Inc. (US) 2021-07-28 EP disclosed
WO-2020061117-A1 FARNESOID X RECEPTOR AGONISTS AND USES THEREOF METACRINE, INC. (US) 2020-03-26 WO disclosed
EP-2743266-B1 PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU FUSION PHARMA (RU) 2016-08-17 EP disclosed
EP-2743266-A2 PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma" (RU) 2014-06-18 EP disclosed
WO-2003040141-A1 OXAZOLYL-PHENYL-2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-05-15 WO disclosed